全球PARP抑制劑生物標記市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

PARP抑制劑生物標記市場預計將從2025年的11.1億美元成長到2034年的24.3億美元，2026年至2034年的複合年成長率為9.11%。

受癌症發病率上升和標靶治療需求增加的推動，PARP抑制劑生物標記市場正經歷顯著成長。 PARP抑制劑是一類在治療具有特定基因突變的癌症（尤其是乳癌和卵巢癌）方面展現出良好前景的藥物。隨著我們對癌症生物學認知的不斷深入，識別和檢驗能夠預測PARP抑制劑療效的生物標記對於個人化醫療至關重要。隨著研究人員和臨床醫生不斷最佳化治療策略並改善患者預後，預計市場將持續擴張。

此外，生物標記發現技術的進步正在推動PARP抑制劑生物標記市場的創新。次世代定序技術、液態生物檢體技術和生物資訊學工具的開發，提高了識別和檢驗與PARP抑制劑療效相關的生物標記的能力。這些創新不僅提高了生物標記檢測的準確性，也加速了伴隨診斷的開發，從而指導治療決策。隨著對新型生物標記及其臨床應用的持續研究，在癌症治療準確性不斷提高的預期推動下，該市場預計將進一步擴張。

此外，對個人化醫療和以患者為中心的治療方式的日益重視正在改變PARP抑制劑生物標記的未來前景。隨著醫療服務提供者越來越重視考慮個別患者特徵的客製化治療方案，對可靠生物標記以指南治療決策的需求預計將會增加。這一趨勢在臨床試驗和藥物研發領域尤其重要，因為生物標記主導的策略可以提高新治療方法的效率和成功率。隨著PARP抑制劑生物標記市場的不斷發展，技術進步、對個人化醫療的關注以及對有效癌症治療的需求將共同作用，在塑造其未來發展軌跡方面發揮關鍵作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球PARP抑制劑生物標記市場：依產品分類

• 市場分析、洞察與預測
• 成套工具
• 偵測

第5章 全球PARP抑制劑生物標記市場：依服務分類

• 市場分析、洞察與預測
• BRCA1 和 BRCA2 檢測
• HRD測試
• H3 測試
• 其他

第6章 全球PARP抑制劑生物標記市場：依應用分類

• 市場分析、洞察與預測
• 乳癌
• 卵巢癌
• 其他

第7章 全球PARP抑制劑生物標記市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Myriad Genetics Inc
  • Ambry Genetics
  • Thermo Fisher Scientific Inc
  • Illumina Inc
  • Centogene NV
  • Amoy Diagnostics Co. Ltd
  • Invitae Corporation
  • NeoGenomics Laboratories
  • QIAGEN
  • Agilent Technologies Inc

The PARP Inhibitor Biomarkers Market size is expected to reach USD 2.43 Billion in 2034 from USD 1.11 Billion (2025) growing at a CAGR of 9.11% during 2026-2034.

The PARP inhibitor biomarkers market is experiencing significant growth, driven by the increasing prevalence of cancer and the rising demand for targeted therapies. PARP inhibitors are a class of drugs that have shown promise in treating cancers with specific genetic mutations, particularly in breast and ovarian cancers. As the understanding of cancer biology advances, the identification and validation of biomarkers that predict response to PARP inhibitors are becoming critical for personalized medicine. This market is expected to expand as researchers and clinicians seek to optimize treatment strategies and improve patient outcomes.

Moreover, advancements in biomarker discovery technologies are propelling innovation within the PARP inhibitor biomarkers market. The development of next-generation sequencing, liquid biopsy techniques, and bioinformatics tools is enhancing the ability to identify and validate biomarkers associated with PARP inhibitor efficacy. These innovations not only improve the accuracy of biomarker testing but also facilitate the development of companion diagnostics that can guide treatment decisions. As research continues to explore new biomarkers and their clinical applications, the market is likely to expand further, driven by the promise of improved precision in cancer therapy.

Additionally, the growing emphasis on personalized medicine and patient-centric approaches is shaping the PARP inhibitor biomarkers landscape. As healthcare providers increasingly prioritize tailored treatment plans that consider individual patient characteristics, the demand for reliable biomarkers that can inform treatment decisions is likely to increase. This trend is particularly relevant in the context of clinical trials and drug development, where biomarker-driven strategies can enhance the efficiency and success rates of new therapies. As the PARP inhibitor biomarkers market continues to evolve, the combination of technological advancements, a focus on personalized medicine, and the need for effective cancer treatments will play a crucial role in shaping its future trajectory.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Kits
• Assays

By Services

• BRCA 1 & 2 Testing
• HRD Testing
• HRR Testing
• Others

By Application

• Breast Cancer
• Ovarian Cancer
• Others

COMPANIES PROFILED

• Myriad Genetics Inc, Ambry Genetics, Thermo Fisher Scientific Inc, Illumina Inc, Centogene NV, Amoy Diagnostics Co Ltd, Invitae Corporation, NeoGenomics Laboratories, QIAGEN, Agilent Technologies Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PARP INHIBITOR BIOMARKERS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Assays Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PARP INHIBITOR BIOMARKERS MARKET: BY SERVICES 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Services
• 5.2. BRCA 1 & 2 Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. HRD Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. HRR Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PARP INHIBITOR BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Ovarian Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PARP INHIBITOR BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Services
  • 7.2.3 By Application
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Services
  • 7.3.3 By Application
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Services
  • 7.4.3 By Application
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Services
  • 7.5.3 By Application
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Services
  • 7.6.3 By Application
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PARP INHIBITOR BIOMARKERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Myriad Genetics Inc
  • 9.2.2 Ambry Genetics
  • 9.2.3 Thermo Fisher Scientific Inc
  • 9.2.4 Illumina Inc
  • 9.2.5 Centogene N.V
  • 9.2.6 Amoy Diagnostics Co. Ltd
  • 9.2.7 Invitae Corporation
  • 9.2.8 NeoGenomics Laboratories
  • 9.2.9 QIAGEN
  • 9.2.10 Agilent Technologies Inc